Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.

ABSTRACT:

Objectives

To estimate additional spending if NHS England paid the same prices as US Medicare Part D for the 50 single-source brand-name drugs with the highest expenditure in English primary care in 2018.

Design

Retrospective analysis of 2018 drug prescribing and spending in the NHS England prescribing data and the Medicare Part D Drug Spending Dashboard and Data. We examined the 50 costliest drugs in English primary care available as brand-name-only in the US and England. We performed cost projections of NHS England spending with US Medicare Part D prices. We estimated average 2018 US rebates as 1 minus the quotient of net divided by gross Medicare Part D spending.

Setting

England and US.

Participants

NHS England and US Medicare systems.

Main outcome measur

SUBMITTER: Liu M 

PROVIDER: S-EPMC7488930 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature